In this month we don’t want to only raise awareness about prevention of colon cancer. We should be aware of the significant progress we have made in the last 10 years treating it.
With the introduction of irinotecan, oxaliplatin, bevacizumab, and cetuximab, overall survival has tripled to more than two years; but this does not tell us the whole story. In the past patients with metastatic disease all died from their disease. This is not true any longer.
With more active therapies, we have cured more and more patients, particularly those whose cancer has only spread to the liver. There are increasing reports that this is also true for lesions found in one site in the lung. Read the rest of this entry »